US 5480656A
· Okada et al.
· 1996
[cited by applicant]
US 5575987A
· Kamei et al.
· 1996
[cited by applicant]
US 5631020A
· Okada et al.
· 1997
[cited by applicant]
US 5643607A
· Okada et al.
· 1997
[cited by applicant]
US 5716640A
· Kamei et al.
· 1998
[cited by applicant]
US 5814342A
· Okada et al.
· 1998
[cited by applicant]
US 6036976A
· Takechi et al.
· 2000
[cited by applicant]
US 6472415B1
· Sovak et al.
· 2002
[cited by applicant]
US 7022870B2
· Dalton et al.
· 2006
[cited by applicant]
US 7118552B2
· Shaw et al.
· 2006
[cited by applicant]
US 7186854B2
· Thijs et al.
· 2007
[cited by applicant]
US 7220247B2
· Shaw et al.
· 2007
[cited by applicant]
US 7500964B2
· Shaw et al.
· 2009
[cited by applicant]
US 7741371B2
· Dalton et al.
· 2010
[cited by applicant]
US 8735440B2
· McKnight et al.
· 2014
[cited by applicant]
US 9550742B2
· Marugan et al.
· 2017
[cited by applicant]
US 9814698B2
· Narayanan et al.
· 2017
[cited by applicant]
US 9815776B2
· Narayanan et al.
· 2017
[cited by applicant]
US 9834507B2
· Narayanan et al.
· 2017
[cited by applicant]
US 20050101657A1
· Furuya et al.
· 2005
[cited by applicant]
US 20060142387A1
· Cadilla et al.
· 2006
[cited by applicant]
US 20060173037A1
· Schlienger et al.
· 2006
[cited by applicant]
US 20070173546A1
· Dalton et al.
· 2007
[cited by applicant]
US 20070265290A1
· Dalton et al.
· 2007
[cited by applicant]
US 20090060873A1
· Sporn et al.
· 2009
[cited by applicant]
US 20090142323A1
· Quarles et al.
· 2009
[cited by applicant]
US 20100227846A1
· Ito et al.
· 2010
[cited by applicant]
US 20110028719A1
· Slon-Usakiewicz
· 2011
[cited by applicant]
US 20130253035A1
· Mcdonnell et al.
· 2013
[cited by applicant]
US 20180028521A1
· Gottardis et al.
· 2018
[cited by applicant]
US 20180271849A1
· Ge et al.
· 2018
[cited by applicant]
US 20210196678A1
· Narayanan et al.
· 2021
[cited by applicant]
CN 1597662A
· 2005
[cited by applicant]
CN 102884057A
· 2013
[cited by applicant]
CN 106551934A
· 2016
[cited by applicant]
EP 0253503
· 1988
[cited by applicant]
EP 0524781A1
· 1993
[cited by applicant]
EP 100172A1
· 2004
[cited by applicant]
EP 2159049A1
· 2010
[cited by applicant]
JP 2008526888A
· 2008
[cited by applicant]
WO WO2001058855A1
· 2001
[cited by applicant]
WO WO2002016310A1
· 2002
[cited by applicant]
WO WO2002046164A1
· 2002
[cited by applicant]
WO WO2002098878
· 2002
[cited by examiner]
WO WO2003074473A2
· 2003
[cited by applicant]
WO WO2003106401A1
· 2003
[cited by applicant]
WO WO2004035737A2
· 2004
[cited by applicant]
WO WO2004035738A2
· 2004
[cited by applicant]
WO WO2005000794A1
· 2005
[cited by applicant]
WO WO2005094531A2
· 2005
[cited by applicant]
WO WO2005120477A2
· 2005
[cited by applicant]
WO WO2006014420A1
· 2006
[cited by applicant]
WO WO2006044359A2
· 2006
[cited by applicant]
WO WO2007005887A2
· 2007
[cited by applicant]
WO WO2007126988A2
· 2007
[cited by applicant]
WO WO2008011072A2
· 2008
[cited by applicant]
WO WO2008044033A1
· 2008
[cited by applicant]
WO WO2008076918A2
· 2008
[cited by applicant]
WO WO2008124000A2
· 2008
[cited by applicant]
WO WO2008137038A1
· 2008
[cited by applicant]
WO WO2009010480A1
· 2009
[cited by applicant]
WO WO2009069736A1
· 2009
[cited by applicant]
WO WO2009082437A2
· 2009
[cited by applicant]
WO WO2012007644A1
· 2012
[cited by applicant]
WO WO2013064681A1
· 2013
[cited by applicant]
WO WO2014113260A1
· 2014
[cited by applicant]
WO WO2015042297A1
· 2015
[cited by applicant]
WO WO2017214634A1
· 2017
[cited by applicant]
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Succesful Synthesis Design, Weinheim: WILEY-VCH Verlg GmbH & Co. KGaA, 2005. (Year: 2005).
[cited by examiner]
Patani et al. Chem. Rev. 1996, 96, 3147-3176 (Year: 1996).
[cited by examiner]
Sheridan, R.P. J. Chem. Inf. Comput. Sci. 2002, 42, 103-108 (Year: 2002).
[cited by examiner]
Andersen et al., “Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor,” Cancer cell, Jun. 15, 2010; 17(6): 535-546.
[cited by applicant]
Antonarakis et al., “AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer,” New England Journal of Medicine, Sep. 11, 2014; 371(11): 1028-1038.
[cited by applicant]
Aradi et al., “DFTB+, a sparse matrix-based implementation of the DFTB method”, J Phys Chem. A. Jul. 5, 2007;111(26): 5678-5684.
[cited by applicant]
Attard et al., “Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer,” Journal of clinical oncology, May 26, 2009; 27(23); 3742-3748.
[cited by applicant]
Baek et al., “Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells” Proceedings of the National Academy of Sciences of the United States of America, Feb. 28, 2006;…
[cited by applicant]
Bassetto et al., “Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer”, Eur J Med Chem. Aug. 8, 2016;118: 230-243.
[cited by applicant]
Berrevoets et al., “Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors,” The Journal of steroid biochemistry and molecular biology, Dec. 31, 1993;…
[cited by applicant]
Bohl et al., “Structural basis for antagonism and resistance of bicalutamide in prostate cancer,” Proceedings of the National Academy of Sciences, Apr. 26, 2005; 102(17): 6201-6206.
[cited by applicant]
Bohl et al., “A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor,” J Med Chem., Jul. 15, 2004; 47(15): 3765-3776.
[cited by applicant]
Bohl et al., “Structural basis for accommodation of nonsteroidal ligands in the androgen receptor,” J Biol. Chem., Nov. 11, 2005; 280(45): 37747-37754.
[cited by applicant]
Bratenko et al., “Polyfunctional pyrazoles. 3 .* Synthesis of 3-(3-aryl-4-formyl-1-pyrazolyl) propionic acids and their amides”, Chem Heter Compounds. Oct. 2004;40(10): 1279-1282.
[cited by applicant]
CAS Registry No. 55734-18-4; STN Entry Date: Nov. 16, 1984.
[cited by applicant]
CAS Registry No. 945553-38-8; STN Entry Date: Aug. 24, 2007.
[cited by applicant]
CAS Registry No. 1349723-51-8; STN Entry Date: Dec. 6, 2011.
[cited by applicant]
CAS Registry No. 1480139-15-8; STN Entry Date: Nov. 24, 2013.
[cited by applicant]
CAS Registry No. 1526624-00-9; STN Entry Date: Jan. 21, 2014.
[cited by applicant]
CAS Registry No. 1839720-91-0; STN Entry Date: Jan. 1, 2016.
[cited by applicant]
CAS Registry No. 1919463-97-0; STN Entry Date: May 27, 2016.
[cited by applicant]
CAS Registry No. 1928217-46-2; STN Entry Date: Nov. 16, 2016.
[cited by applicant]
Choi et al., “Collision tumor of hepatocellular carcinoma and neuroendocrine carcinoma involving the liver: case report and review of the literature”, World J Gastroenterol. Nov. 7, 2016;22(41): 9229-9234.
[cited by applicant]
Claessens et al., “Diverse roles of androgen receptor (AR) domains in AR-mediated signaling,” J Nucl Recep Signal. Jun. 27, 2008; 6:e008 in 13 pages.
[cited by applicant]
Clegg et al., “ARN-509: A novel antiandrogen for prostate cancer treatment,” Cancer Res., Mar. 15, 2012; 72(6): 1494-1503.
[cited by applicant]
ClinicalTrials.gov; “Enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior therapies”, Study Sponsor: Memorial Sloan Kettering Ca…
[cited by applicant]
Colin et al., “New Access to fluorinated ketoglycolic acid derivatives from trifluoropyruvamides”, Tetrahe Letts. Jul. 12, 2004;45(29): 5611-5613.
[cited by applicant]
Dalvit et al., “Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water”, J Biomolecular NMR. Sep. 2000;18(1): 65-68.
[cited by applicant]
Danquah et al., “Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer,” Pharma Res., Aug. 1, 2012; 29(8): 2079-2091.
[cited by applicant]
DATABASE Caplus Chemical Abstracts Service; Database Accession No. 2005: 14358, Abstract of WO 2005000794, published, Jan. 6, 2005; in 9 pages.
[cited by applicant]
De Bono et al., “Abiraterone and increased survival in metastatic prostate cancer,” N Eng J Med., May 26, 2011; 364(21): 1995-2005.
[cited by applicant]
Dehm et al., “Alternatively spliced androgen receptor variants,” Endocrine-related Cancer, Oct. 1, 2011; 18(5): R183-R196.
[cited by applicant]
Dehm et al., “Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance,” Cancer Res., Jul. 1, 2008; 68(13): 5469-5477.
[cited by applicant]
Dias et al., “NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes”, Prog Biophys Mol Biol. Nov. 1, 2014;116(2-3): 101-112.
[cited by applicant]
Duke III, Charles B., et al., “Synthesis and biological studies of androgen receptor ligands: Towards mutation-resistant nonsteroidal antagonism,” Abstract of Papers of the American Chemical Society, vol. 240, 1155; 16t…
[cited by applicant]
Elstner et al., “Self-consistent-charge density-functional tight-binding method for simulations of complex materials properties”, Phys Rev B. Sep. 15, 1998;58(11): 7260-7268.
[cited by applicant]
Epps et al., “Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein”, J Pharm Pharmacol. Jan. 1999;51(1): 41-48.
[cited by applicant]
Gal et al., “Efficient isothermal titration calorimetry technique identifies direct interation of small molecule inhibitors with the target protein”, Combin Chem High Throughput Screen. Jan. 1, 2016;19(1): 4-13.
[cited by applicant]
Gibson et al., “Evidence of androgen action in endometrial and ovarian cancers”, Endocrine-related cancer. Aug. 1, 2014;21(4): T203-T218.
[cited by applicant]
Gottlieb et al., “Androgen insensitivity syndrome”, University of Washington, Seattle (WA) Publication, initial Posting: Mar. 24, 1999; last Update: May 11, 2017, in 15 pages.
[cited by applicant]
Hara et al., “Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome”, Cancer Res. Jan. 1, 2003;63(1): 149-153.
[cited by applicant]
He et al., “ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF Signaling Pathway”, Cancer Res. Aug. 2014.; 74(16): 4420-4430.
[cited by applicant]
Hebenbrock K-F., “Preparation and reaction of 1-aryl-3-hydroxy-3-methyl-2,5-pyrrolidinediones”, Justus Liebig's Annals of Chemistry, Aug. 1, 1978;vol. 2, pp. 320-336 (Abstract).
[cited by applicant]
Hu et al., “Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer,” Cancer Res., Jul. 15, 2012; 72(14): 3457-346…
[cited by applicant]
Hwang et al., “Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer,” Bioorg Med Chem., Oct. 1, 2006; 14(19): 6525-6538.
[cited by applicant]
Isikbay et al., “Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer”, Horm Cancer. Apr. 2014;5(2): 72-89.
[cited by applicant]
Jin et al., “Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-ß type 1 receptor kinase inhibitors,” Euro J Med Chem. (2011)46: 3…
[cited by applicant]
Jin et al., “Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-ß type 1 receptor kinase inhibitors”, Bioorg Med Chem. 2011;19: 2633…
[cited by applicant]
Kamal et al., “Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival”, Br J Cancer. Mar. 2016;114(6): 688-696.
[cited by applicant]
Kim et al., “Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability,” Oncotarget, Feb. 1, 2014; 5(4): 860-71.
[cited by applicant]
Klotz L., “Maximal androgen blockade for advanced prostate cancer,” Best Pract Res Clin Endocrin Metabol., Apr. 30, 2008; 22(2): 331-340.
[cited by applicant]
Kominea et al., “Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer”, J Cancer Res Clin Oncol. May 2004;130(5): 253-258.
[cited by applicant]
La Spada et al., “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy”, Nature. Jul. 1991;352(6330): 77-79.
[cited by applicant]
Lazar et al., “Hyperandrogenism as a cause of early polycystic ovary syndrome (PCOS) in girls with central precocious puberty (CPP)”, Pediatric Research. May 1993;33(5): S14; Abstract 64.
[cited by applicant]
Li et al., “On the physical origin of blue-shifted hydrogen bonds”, J Am Chem Soc. Aug. 14, 2002;124(32): 9639-9647.
[cited by applicant]
Li et al., “Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines,” Cancer Res., Jan. 15, 2012; 73(2): 483-489.
[cited by applicant]
Lieberman et al., [Eds.] Pharmaceutical Dosage Forms: Tablets; Marcel Dekker, 1989, TOC in 11 pages.
[cited by applicant]
Maclean et al., “Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion,” Journal of the neurological sciences, Feb. 29, 1996; 135(2): 149-57.
[cited by applicant]
Marhefka et al., “Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands,” J Med Chem., Ma…
[cited by applicant]
Marhefka et al., “Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators,” J Med Chem., Feb. 12, 2004; 47(4): 993-998.
[cited by applicant]
Mayo Clinic, “Uterine Fibroids - Overview”, Mayo Clinic Staff; printed Aug. 7, 2017; 2 pages.
[cited by applicant]
McGinley et al., “Circumventing anti-androgen resistance by molecular design,” J Am Chem Soc., Apr. 4, 2007; 129(13): 3822-3823.
[cited by applicant]
Mikkonen et al., “Androgen receptor and androgen-dependent gene expression in lung”, Mol Cell Endocrinol. Apr. 12, 2010;317(1-2): 14-24.
[cited by applicant]
Miller D.D., “Irreversible Nonsteroida SARMs for Prostate Cancer”, Aug. 15, 2003;online at http://grantome.com/grant/NIH/R01-DK065227-20, 2003, 4 pages.
[cited by applicant]
Mitsiades N., “A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer,” Cancer Res., Aug. 1, 2013; 73(15): 4599-4605.
[cited by applicant]
Mohler et al., “Nonsteroidal selective androgen receptor modulators (SARMs): Dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit”, J Med Chem., Jun. 2009;52(12): 3597-361…
[cited by applicant]
Mohler et al., “Androgen receptor antagonists: a patent review (2008-2011),” Expert Opinion Ther. Patents, (2012): 22(5): 541-565.
[cited by applicant]
Monge et al., “Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer,” Cell Mol Life Sci., Feb. 1, 2006; 63(4): 487-497.
[cited by applicant]
Morris et al., “Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens”, J Med Chem. Jan. 1991…
[cited by applicant]
Morvillo et al., “Androgen receptors in human melonoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases”, Melanomoa Res. Dec. 2002;12(6): 529-538 [Abstract].
[cited by applicant]
Mostaghel et al., “Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications”, Exp Hematol. May 2017;49: 34-38.e2.
[cited by applicant]
Munoz et al., “Androgen receptors beyond prostate cancer: An old marker as a new target”, Oncotarget. Jan. 2015;6(2): 592-603.
[cited by applicant]
Nagata et al., “Preparation and reactions of cyclic a-monocarbonyl azo-compounds: 1-pyrazolin-3-one derivatives”, J Chem Soc. C: Organic. 1970(4): 540-550.
[cited by applicant]
Narayanan et al., “Biological synthesis of metal nanoparticles by microbes”, Adv Colloid Interface Science. Apr. 22, 2010;156(1-2): 1-3.
[cited by applicant]
Narayanan et al., “Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial: Mesenchymal Stem Cell Signaling,” PLOS ONE, Jul. 2014; 9(7): 1-12.
[cited by applicant]
Nazareth et al., “Activation of the human androgen receptor through a protein kinase A signaling pathway,” J Biol Chem., Aug. 16, 1996; 271(33): 19900-19907.
[cited by applicant]
Nyquist et al., “TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer,” Proc Nat Acad. Sci., Oct. 22, 2013; 110(43): 17492-17497.
[cited by applicant]
Park et al., “Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma”, Transl Oncol. Jun. 1, 2013;6(3): 370-381.
[cited by applicant]
Ponnusamy et al., “Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer,” Cancer Res. (2017); 77(22): 6282-6298.
[cited by applicant]
Pubchem, CID 3145286.09, Aug. 9, 2005, pp. 1-12; retrieved from the Internet <URL: https:Ilpubchem.ncbl.nlm.nih.gov/compound/3145286> in 12 pages.
[cited by applicant]
Pubmed, CID 20221988, “Compound Summary for CID 20221988-C12H13N30”; Dec. 5, 2007, pp. 1-11; retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/compound/20221988>.
[cited by applicant]
Rawel et al., “Determining the binding affinities of phenolic compounds to proteins by quenching of the intrinsic tryptophan fluorescence”, Mol Nutri Food Res. Aug. 2006;50(8): 705-713.
[cited by applicant]
Gennaro A.R. [Ed.], “Remington's pharmaceutical sciences”, Mack Publishing Company, 18th Edition; 1990, TOC in 6 pages.
[cited by applicant]
Rowe R.C. [Ed.], “Handbook Of Pharmaceutical Excipients”, American Pharmaceutical Association; Fifth Edition, 2006, TOC in 6 pages.
[cited by applicant]
Rygula et al., “Raman spectroscopy of proteins: a review”, J Raman Spectrosc. Aug. 2013;44(8): 1061-1076.
[cited by applicant]
Sadar M.D., “Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase a signal transduction pathways,” J Biol Chem., Mar. 19, 1999; 274(…
[cited by applicant]
Sadar et al., “Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells,” Cancer Res., Oct. 15, 2000; 60(20): 5825-5831.
[cited by applicant]
Sartor et al., “Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer,” Asian J Andrology, May 2015; 17(3): 439-440.
[cited by applicant]
Scher et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” N Eng J Med., Sep. 27, 2012; 367(13): 1187-1197.
[cited by applicant]
Schragl et al., “Novel pathway for the synthesis of arylpropionamide-derived selective androgen receptor modulator (SARM) metabolites of andarine and ostarine”, Tetra Lettrs. May 1, 2013;54(18): 2239-2242.
[cited by applicant]
Seligson et al., “Development of Fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia”, Drug Devel Res. Jul. 2003;59(3): 292-306.
[cited by applicant]
Shortridge et al., “Estimating protein-ligand binding affinity using high-throughput screening by NMR”, J Comb Chem. Nov. 10, 2008;10(6): 948-958.
[cited by applicant]
Sieber PR., “Treatment of bicalutamide-induced breast events,” Exp Review Anticancer Thera., Dec. 1, 2007; 7(12): 1773-1779.
[cited by applicant]
Siegel et al., “Cancer statistics, 2014” CA Cancer. J. Clin., 2014; 64: 9-29.
[cited by applicant]
Simanainen et al., “Androgen receptor actions modify skin structure and chemical carcinogen-induced skin cancer susceptibility in mice”, Hormones and Cancer. Feb. 2015;6(1): 45-53.
[cited by applicant]
Soper et al., “Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy”, Head Neck. Jan. 2014;36(1): E4-E7.
[cited by applicant]
Sukocheva et al., “Androgens and esophageal cancer: What do we know?” World J Gastroenterol. May 28, 2015;21(20): 6146-6156.
[cited by applicant]
Tan et al., “Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells”, Mol Endocrin. Apr. 1, 1997;11(4): 450-459.
[cited by applicant]
Tangen et al., “Androgen receptor as potential therapeutic target in metastatic endometrial cancer”, Oncotarget. Aug. 2, 2016;7(31): 49289-49298.
[cited by applicant]
Tarikogullari et al., “Synthesis and anticonvulsant activity of some alkanamide derivatives”, Arzneimittelforschung. Oct. 2010;60(10): 593-598 (Abstract).
[cited by applicant]
Tran et al., “Development of a second-generation antiandrogen for treatment of advanced prostate cancer,” Science, May 8, 2009; 324(5928): 787-790.
[cited by applicant]
Tucker et al., “Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides”, J Med Chem. May 1988;31(5): 954-959.
[cited by applicant]
Tutton et al., “The influence of androgens, anti-androgens, and castration on cell proliferation in the jejunal and colonic crypt epithelia, and in dimehylhydrazine-induced adenocarcinoma of rat colon”, Virchows Arch B …
[cited by applicant]
Ueda et al., “Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells,” J Biol Chem., Oct. 11, 2002; 277(41): 38087-38094.
[cited by applicant]
Wang et al., “Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1”, Mol Endocrin. Dec. 1, 2011;25(12): 2041-2053.
[cited by applicant]
Wang et al., “Effects of hydrogen bond and solvent polarity on the C=O stretching of bis (2-thienyl)ketone in solution”, J Chem Physics. Mar. 28, 2012;136(12): 03B614.
[cited by applicant]
Watson et al., “Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor”, PNAS. Sep. 28, 2010;107(39): 16759-16765.
[cited by applicant]
Weiner L.P., “Possible role of androgen receptors in amyotrophic lateral sclerosis: a hypothesis,” Arch Neurol. Mar. 1, 1980; 37(3): 129-131 (Abstract).
[cited by applicant]
Wen et al., “LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer,” Pharma Res., Oct. 1, 2014; 31(10): 2784-2795.
[cited by applicant]
Wen et al., “Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells”, Mol Carcino. Dec. 2016;55(12): 2278-2290.
[cited by applicant]
West A.R., “Solid state chemistry and its applications”, John Wiley & Sons; 1988; Chapter 10; pp. 358, 365.
[cited by applicant]
Wikipedia, “Hyperandrogenism”, downloaded Aug. 7, 2017 in 8 pages.
[cited by applicant]
Wong et al., “Circulating sex hormones and risk of uterine fibroids: Study of women's health across the nation (SWAN),” J Clin Endocrinol. Jan. 1, 2016;101(1): 123-130.
[cited by applicant]
Xu et al., “hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas,” Oncogene, May 12, 2011; 30(19): 2219-29.
[cited by applicant]
Yamashita et al., “ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors,” Neoplasia, Jan. 1, 2012;14(1): 74-83.
[cited by applicant]
Yepuru et al., “Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth”, Clin Cancer Res. Oct. 15, 2013;19(20): 5613-5625.
[cited by applicant]
Yoshida et al., “Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient,” Cancer Res., Nov. 1, 2005; 65(21): 9611-9616.
[cited by applicant]
Yu et al., “Androgen receptor signaling regulates growth of glioblastoma multiforme in men”, Tumour Biol. Feb. 2015;36(2): 967-972 [Abstract].
[cited by applicant]
Zhou et al., “Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens,” Proteins: Structure, Function, and Bioinf…
[cited by applicant]
International Search Report dated Dec. 24, 2019.
[cited by applicant]
Aggarwal, et al. “Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis.” Neurobiology of Aging 35.8 (2014): 1929-1938.
[cited by applicant]
Antonarakis, et al., “Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first-and second-line …
[cited by applicant]
Arora, et al. “Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.” Cell 155.6 (2013): 1309-1322.
[cited by applicant]
Baniahmad, Aria. “Inhibition of the androgen receptor by antiandrogens in spinobulbar muscle atrophy.” Journal of Molecular Neuroscience 58.3 (2016): 343-347.
[cited by applicant]
Bryce, et al., “Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.” International Journal of Urology 23.8 (2016): 646-653. doi: 10.1111/iju.13134.
[cited by applicant]
Cochrane et al., Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide., Breast Cancer Res. (2014) 16(1): R7, pp. 1-19.
[cited by applicant]
Davis, et al. “Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.” Journal of vascular surgery 63.6 (2016): 1602-1612.
[cited by applicant]
Galbiati, et al. “The anabolic/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis.” Pharmacological research 65.2 (2…
[cited by applicant]
Hsieh, et al. “Androgen receptor trinucleotide polymorphism in leiomyoma.” Journal of assisted reproduction and genetics 21.12 (2004): 453-457.
[cited by applicant]
International Preliminary Report on Patentability from PCT/US2019/049769 dated Mar. 18, 2021.
[cited by applicant]
Joseph, et al. “A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.” Cancer discovery 3.9 (2013): 1020-1029.
[cited by applicant]
Kanda et al. “Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers”., World J. Gastroenterology Jul. 2014, 20(29), 9229-9236.
[cited by applicant]
Kawahara, et al. “ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.” Oncotarget 6.30 (2015): 29860-29876.
[cited by applicant]
Lallous, et al. “Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.” Genome biology 17.1 (2016): 1-15.
[cited by applicant]
Lieberman, et al. “Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy.” Cell reports 7.3 (2014): 774-784.
[cited by applicant]
Locati, et al. “Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.” Head & neck 38.5 (2016): 724-731.
[cited by applicant]
McBeth et al., “Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer”. International journal of endocrinology 2015 (2015), pp. 1-11. Article ID 384860.
[cited by applicant]
Miller, et al. “Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.” Prostate cancer and prostatic diseases 16.2 (…
[cited by applicant]
Renier, et al. “Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.” Endocrinology 155.7 (2014): 2624-2634.
[cited by applicant]
Rosa, et al. “Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas.” Clinical Chemistry and Laboratory Medicine (CCLM) 46.6 (2008): 814-823.
[cited by applicant]
Sun et al. “Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.” The Journal of clinical investigation 120.8 (2010): 2715-2730.
[cited by applicant]